These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33087358)

  • 1. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease.
    Higginbotham L; Ping L; Dammer EB; Duong DM; Zhou M; Gearing M; Hurst C; Glass JD; Factor SA; Johnson ECB; Hajjar I; Lah JJ; Levey AI; Seyfried NT
    Sci Adv; 2020 Oct; 6(43):. PubMed ID: 33087358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.
    Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.
    Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
    Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
    Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease.
    Boeddrich A; Haenig C; Neuendorf N; Blanc E; Ivanov A; Kirchner M; Schleumann P; Bayraktaroğlu I; Richter M; Molenda CM; Sporbert A; Zenkner M; Schnoegl S; Suenkel C; Schneider LS; Rybak-Wolf A; Kochnowsky B; Byrne LM; Wild EJ; Nielsen JE; Dittmar G; Peters O; Beule D; Wanker EE
    Genome Med; 2023 Jul; 15(1):50. PubMed ID: 37468900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease.
    Bader JM; Geyer PE; Müller JB; Strauss MT; Koch M; Leypoldt F; Koertvelyessy P; Bittner D; Schipke CG; Incesoy EI; Peters O; Deigendesch N; Simons M; Jensen MK; Zetterberg H; Mann M
    Mol Syst Biol; 2020 Jun; 16(6):e9356. PubMed ID: 32485097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery.
    Bai B; Vanderwall D; Li Y; Wang X; Poudel S; Wang H; Dey KK; Chen PC; Yang K; Peng J
    Mol Neurodegener; 2021 Aug; 16(1):55. PubMed ID: 34384464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
    Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
    J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
    Dammer EB; Ping L; Duong DM; Modeste ES; Seyfried NT; Lah JJ; Levey AI; Johnson ECB
    Alzheimers Res Ther; 2022 Nov; 14(1):174. PubMed ID: 36384809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.
    van der Ende EL; In 't Veld SGJG; Hanskamp I; van der Lee S; Dijkstra JIR; Hok-A-Hin YS; Blujdea ER; van Swieten JC; Irwin DJ; Chen-Plotkin A; Hu WT; Lemstra AW; Pijnenburg YAL; van der Flier WM; Del Campo M; Teunissen CE; Vermunt L
    Brain; 2023 Nov; 146(11):4495-4507. PubMed ID: 37348871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease.
    Johnson ECB; Dammer EB; Duong DM; Yin L; Thambisetty M; Troncoso JC; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2018 Oct; 13(1):52. PubMed ID: 30286791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer's disease biomarkers.
    Górska AM; Santos-García I; Eiriz I; Brüning T; Nyman T; Pahnke J
    J Neurosci Methods; 2024 Nov; 411():110239. PubMed ID: 39102902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression.
    Bai B; Wang X; Li Y; Chen PC; Yu K; Dey KK; Yarbro JM; Han X; Lutz BM; Rao S; Jiao Y; Sifford JM; Han J; Wang M; Tan H; Shaw TI; Cho JH; Zhou S; Wang H; Niu M; Mancieri A; Messler KA; Sun X; Wu Z; Pagala V; High AA; Bi W; Zhang H; Chi H; Haroutunian V; Zhang B; Beach TG; Yu G; Peng J
    Neuron; 2020 Mar; 105(6):975-991.e7. PubMed ID: 31926610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
    Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
    Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics.
    Gaetani L; Bellomo G; Parnetti L; Blennow K; Zetterberg H; Di Filippo M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Candidate Biomarkers of Alzheimer's Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics.
    Liu P; Li L; He F; Meng F; Liu X; Su Y; Su X; Luo B; Peng G
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review.
    Strac DS; Muck-Seler D; Pivac N
    Psychiatr Danub; 2015 Mar; 27(1):14-24. PubMed ID: 25751428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
    Wildsmith KR; Schauer SP; Smith AM; Arnott D; Zhu Y; Haznedar J; Kaur S; Mathews WR; Honigberg LA
    Mol Neurodegener; 2014 Jun; 9():22. PubMed ID: 24902845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.
    Bastos P; Ferreira R; Manadas B; Moreira PI; Vitorino R
    Crit Rev Clin Lab Sci; 2017 May; 54(3):185-204. PubMed ID: 28393582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.